Mao, H.H. and Chao, S. (2020) Advances in Vaccines. In: Silva, A.C., Moreira, J.N., Lobo, J.M.S. and Almeida, H., Eds., Current Applications of Pharmaceutical Biotechnology, Vol. 171, Springer, Cham, 155-188.
https://doi.org/10.1007/10_2019_107

has been cited by the following article:

• TITLE: Zika Virus and Its Association with Neurological Disorders

  AUTHORS: Dama Faniriantsoa Henrio Marcellin, Limin Guo, Haiyang Yu, Shuchao Wang, Paul Pielnaa, Adonira Saro, Ismail Bilal Masokano, Malik Muhammad Adil, Ling Yuan, Yanxia Huang, Deyang Cai, Ruping Zheng, Zhongjun Huang, Aixiang Luo, Cyrollah Disoma, Pinjia Liu, Zanxian Xia, Jufang Huang

  KEYWORDS: Zika Virus (ZIKV), Microcephaly, Guillain Barré Syndrome, Epilepsy, Neurological Disorders

  JOURNAL NAME: Advances in Microbiology, Vol.12 No.4, April 18, 2022

  ABSTRACT: Zika virus (ZIKV) is a flavivirus that can be identified as a small envelope with a positive-stranded RNA and an important medical pathogen, which causes deadly human diseases. The virus is carried by Aedes aegypti mosquitoes through a blood meal and it is also spread through body fluids. ZIKV infection may present with symptoms like fever, myalgia, maculopapular rash as well as neurological sequelae, which include, microcephaly, epilepsy, and Guillain Barré syndrome (GBS). This put the virus on a scale of the public health burden of almost 87 countries. The potential threat of ZIKV infection is not completely eradicated in many countries in Africa, America, and the Western Pacific regions. There are no vaccines and treatments available to date. Since ZIKV causes microcephaly in utero by targeting neural progenitor cells, inducing apoptosis, and impairing neurodevelopment, this article hopes to evaluate the neurological disorders associated with the Zika virus infection while elucidating the current trends in the development of vaccines and drugs.